Unknown

Dataset Information

0

In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance.


ABSTRACT: Many drugs are effective in the early stage of treatment, but patients develop drug resistance after a certain period of treatment, causing failure of the therapy. An important example is Herceptin, a popular monoclonal antibody drug for breast cancer by specifically targeting human epidermal growth factor receptor 2 (Her2). Here we demonstrate a quantitative binding kinetics analysis of drug-target interactions to investigate the molecular scale origin of drug resistance. Using a surface plasmon resonance imaging, we measured the in situ Herceptin-Her2 binding kinetics in single intact cancer cells for the first time, and observed significantly weakened Herceptin-Her2 interactions in Herceptin-resistant cells, compared to those in Herceptin-sensitive cells. We further showed that the steric hindrance of Mucin-4, a membrane protein, was responsible for the altered drug-receptor binding. This effect of a third molecule on drug-receptor interactions cannot be studied using traditional purified protein methods, demonstrating the importance of the present intact cell-based binding kinetics analysis.

SUBMITTER: Wang W 

PROVIDER: S-EPMC4196117 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

In situ drug-receptor binding kinetics in single cells: a quantitative label-free study of anti-tumor drug resistance.

Wang Wei W   Yin Linliang L   Gonzalez-Malerva Laura L   Wang Shaopeng S   Yu Xiaobo X   Eaton Seron S   Zhang Shengtao S   Chen Hong-Yuan HY   LaBaer Joshua J   Tao Nongjian N  

Scientific reports 20141014


Many drugs are effective in the early stage of treatment, but patients develop drug resistance after a certain period of treatment, causing failure of the therapy. An important example is Herceptin, a popular monoclonal antibody drug for breast cancer by specifically targeting human epidermal growth factor receptor 2 (Her2). Here we demonstrate a quantitative binding kinetics analysis of drug-target interactions to investigate the molecular scale origin of drug resistance. Using a surface plasmo  ...[more]

Similar Datasets

| S-EPMC8303735 | biostudies-literature
| S-EPMC5658366 | biostudies-literature
| S-EPMC6838936 | biostudies-literature
| S-EPMC4151789 | biostudies-other
| S-EPMC3660014 | biostudies-literature
| S-EPMC7567407 | biostudies-literature
| S-EPMC3783941 | biostudies-literature
| S-EPMC3587579 | biostudies-literature
| S-EPMC3928317 | biostudies-literature
| S-EPMC7859943 | biostudies-literature